Smith & Nephew SNATS (SNN) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
10x Genomics (TXG) has outperformed Smith & Nephew SNATS (SNN) over the past year, gaining 540.3% versus a loss of 25.0%. Over five years, SNN leads with a -23.8% price change compared with -49.2% for TXG. Smith & Nephew SNATS is the larger company by market cap ($11.28 billion vs $10.07 billion), about 1.1 times the size.
On valuation, Smith & Nephew SNATS trades at a lower forward P/E (11.2x vs 1008.0x for 10x Genomics). Smith & Nephew SNATS pays a dividend yielding 1.47%, while 10x Genomics does not currently pay one. Smith & Nephew SNATS converts more of its revenue into profit, with a net margin of 10.1% versus -6.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNN | TXG |
|---|---|---|
| Share price | $26.96 | $77.28 |
| Market cap | $11.28B | $10.07B |
| 1-day change | +0.26% | +1.55% |
| YTD return | -17.83% | +373.82% |
| 1-year return | -24.97% | +540.27% |
| 5-year return | -23.82% | -49.25% |
| P/E ratio (TTM) | 18.34 | — |
| Forward P/E | 11.18 | — |
| EPS (TTM) | $1.47 | $-0.59 |
| Dividend yield | 1.47% | 0.00% |
| Annual dividend | $0.397 | $0.00 |
| Revenue (latest FY) | $6.16B | $642.82M |
| Revenue growth (YoY) | +6.09% | +5.25% |
| Net income (latest FY) | $625.00M | $-43.54M |
| Gross margin | 68.01% | 69.05% |
| Operating margin | 12.88% | -9.49% |
| Net margin | 10.14% | -6.77% |
| 52-week high | $37.51 | $102.81 |
| 52-week low | $26.12 | $11.16 |
| Distance from 52-week high | -28.13% | -24.83% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +19.88% | -12.69% |
| Average volume | 1.65M | 3.29M |
| Shares outstanding | 418.52M | 120.21M |
| Employees | 17,000 | 1,178 |
| Sector | Health Care | Industrials |
| Industry | Industrial Specialties | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TXG has outperformed SNN by 565.2 percentage points over the past year.
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.47% vs 0.00%).
- Smith & Nephew SNATS is more profitable, keeping 10.1 cents of every revenue dollar as net income versus -6.8 cents for 10x Genomics.
- The two companies sit in different sectors: Smith & Nephew SNATS in Health Care and 10x Genomics in Industrials.
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Health Care · Industrial Specialties · 17,000 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
SNN vs TXG FAQ
Which is bigger, Smith & Nephew SNATS or 10x Genomics?
Smith & Nephew SNATS (SNN) is larger, with a market capitalization of $11.28B compared with $10.07B for 10x Genomics (TXG).
Which stock has performed better over the past year, SNN or TXG?
TXG returned +540.27% over the past 12 months, compared with -24.97% for SNN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Smith & Nephew SNATS or 10x Genomics?
Smith & Nephew SNATS pays a dividend yielding 1.47%, while 10x Genomics does not currently pay a regular dividend.
Are Smith & Nephew SNATS and 10x Genomics in the same industry?
No. Smith & Nephew SNATS is in the Health Care sector, while 10x Genomics is in Industrials.